靶向治疗：深入近期贝伐单抗试验的表面之下探寻峰值 - Suppr

Targeted therapies: peaking beneath the surface of recent bevacizumab trials.

作者信息

Gonzalez-Angulo Ana M, Hortobagyi Gabriel N, Ellis Lee M

出版信息

Nat Rev Clin Oncol. 2011 Jun;8(6):319-20. doi: 10.1038/nrclinonc.2011.66. Epub 2011 Apr 19.

DOI:10.1038/nrclinonc.2011.66

PMID:21556024

Abstract

摘要

相似文献

Targeted therapies: peaking beneath the surface of recent bevacizumab trials.

Nat Rev Clin Oncol. 2011 Jun;8(6):319-20. doi: 10.1038/nrclinonc.2011.66. Epub 2011 Apr 19.

Monoclonal antibody therapies shine in breast cancer clinical trials.

JAMA. 2005 Jun 22;293(24):2985-9. doi: 10.1001/jama.293.24.2985.

Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.

Clin Breast Cancer. 2010 Sep;10 Suppl 2:S30-40. doi: 10.3816/CBC.2010.s.010.

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. doi: 10.6004/jnccn.2007.0026.

[ASCO 2005: biology has spoken!].

Bull Cancer. 2005 Jul;92(7):623-4.

Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.

Drugs. 2006;66(12):1577-91. doi: 10.2165/00003495-200666120-00004.

HER2-targeted therapies: how far we've come--and where we're headed.

Oncology (Williston Park). 2011 Apr 30;25(5):425-6.

Success of bevacizumab trials raises questions for future studies.

J Natl Cancer Inst. 2005 Jul 6;97(13):950-1. doi: 10.1093/jnci/dji194.

Can cancer clinical trials be fixed?

Nat Biotechnol. 2011 Jan;29(1):13-5. doi: 10.1038/nbt.1746.

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.

Tumori. 2016 Oct 13;102(5):472-480. doi: 10.5301/tj.5000555. Epub 2016 Aug 23.

引用本文的文献

Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.

Cancer Res. 2022 Apr 15;82(8):1658-1668. doi: 10.1158/0008-5472.CAN-21-0626.

Rational design of non-resistant targeted cancer therapies.

Sci Rep. 2017 Apr 24;7:46632. doi: 10.1038/srep46632.

A streamlined search technology for identification of synergistic drug combinations.

Sci Rep. 2015 Sep 29;5:14508. doi: 10.1038/srep14508.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Angiogenesis. 2015 Jul;18(3):233-44. doi: 10.1007/s10456-015-9462-9. Epub 2015 Apr 1.

Evolutionary dynamics of cancer in response to targeted combination therapy.

Elife. 2013 Jun 25;2:e00747. doi: 10.7554/eLife.00747.

Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

Adv Exp Med Biol. 2013;734:91-107. doi: 10.1007/978-1-4614-1445-2_6.

Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.

Clin Exp Immunol. 2012 Feb;167(2):188-94. doi: 10.1111/j.1365-2249.2011.04514.x.

Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.

Cancer Res. 2012 Feb 15;72(4):854-64. doi: 10.1158/0008-5472.CAN-11-2795. Epub 2012 Jan 5.

Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Mol Oncol. 2011 Dec;5(6):492-503. doi: 10.1016/j.molonc.2011.10.005. Epub 2011 Oct 25.

Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Nat Rev Cancer. 2011 Sep 23;11(10):735-48. doi: 10.1038/nrc3125.

本文引用的文献

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

J Clin Oncol. 2011 Apr 1;29(10):1232-5. doi: 10.1200/JCO.2010.33.2684. Epub 2011 Mar 7.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

J Clin Oncol. 2011 Mar 20;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455. Epub 2011 Feb 14.

JAMA. 2011 Feb 2;305(5):487-94. doi: 10.1001/jama.2011.51.

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

J Clin Oncol. 2011 Jan 1;29(1):83-8. doi: 10.1200/JCO.2010.30.2794. Epub 2010 Nov 22.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24.

Optimal schedule of paclitaxel: weekly is better.

J Clin Oncol. 2008 Apr 1;26(10):1585-7. doi: 10.1200/JCO.2007.15.7651.

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

N Engl J Med. 2007 Dec 27;357(26):2666-76. doi: 10.1056/NEJMoa072113.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeted therapies: peaking beneath the surface of recent bevacizumab trials.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献